The Commerce Commission has received a clearance application from Mylan N.V. and Upjohn Inc. to merge their global
pharmaceutical businesses. Upjohn is a wholly owned subsidiary of Pfizer Inc.
Mylan is a US-based global pharmaceutical company that develops, licenses, manufactures, and distributes branded generic
and specialty pharmaceuticals.
Upjohn is the division of Pfizer that operates Pfizer’s off-patent branded and generic established medicines business
and is headquartered in China.
In New Zealand, both parties supply off-patent prescription medicines including cholesterol and triglyceride regulators,
non-steroidal antirheumatics, antiepileptics and erectile dysfunction products.
A public version of the clearance application is available on the Commission’s case register.
Background
We will give clearance to a proposed merger if we are satisfied that the merger is unlikely to have the effect of
substantially lessening competition in a market.
Further information explaining how the Commission assesses a merger application is available on our website.